Dominic J. Caruso net worth and biography

Dominic Caruso Biography and Net Worth

VP of Johnson & Johnson

Mr. Caruso retired as executive vice president and chief financial officer from Johnson & Johnson in August 2018, having served in the role since 2007. He led the company’s financial and investor relations activities, as well as the procurement organization. Mr. Caruso joined Johnson & Johnson in October 1999 as chief financial officer for Centocor, Inc., upon the completion of the merger of Centocor and Johnson & Johnson. Prior to joining Centocor, he had varied industry experiences with KPMG. Mr. Caruso is actively involved in government relations activities globally, including having served as the co-chair of the U.S. Chamber of Commerce Global Initiative on Health and the Economy. He currently serves on the board of trustees of The Children’s Hospital of Philadelphia, the Cystic Fibrosis Foundation and is on the board of directors for Kyndryl Inc. Mr. Caruso has been a director of the Company since September 2018. He is chair of the Audit Committee and a member of the Compliance Committee.

What is Dominic J. Caruso's net worth?: The estimated net worth of Dominic J. Caruso is at least $32.75 million as of July 20th, 2017. Mr. Caruso owns 226,693 shares of Johnson & Johnson stock worth more than $32,750,338 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Caruso may own. Learn More about Dominic J. Caruso's net worth.
How do I contact Dominic J. Caruso?: The corporate mailing address for Mr. Caruso and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400 and via email at [email protected]. Learn More on Dominic J. Caruso's contact information.
Has Dominic J. Caruso been buying or selling shares of Johnson & Johnson?: Dominic J. Caruso has not been actively trading shares of Johnson & Johnson during the last quarter. Most recently, Dominic J. Caruso sold 82,591 shares of the business's stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a transaction totalling $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company's stock, valued at $30,993,466.96. Learn More on Dominic J. Caruso's trading history.
Who are Johnson & Johnson's active insiders?: Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Chairman), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), James Swanson (EVP), Jennifer Taubert (EVP), Mark Weinberger (Director), Kathryn Wengel (EVP), Joseph Wolk (CFO), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.
Are insiders buying or selling shares of Johnson & Johnson?: During the last year, Johnson & Johnson insiders bought shares 1 times. They purchased a total of 1,000 shares worth more than $147,220.00. During the last year, insiders at the sold shares 3 times. They sold a total of 68,757 shares worth more than $10,308,224.54. The most recent insider tranaction occured on December, 12th when Director Mark A Weinberger bought 1,000 shares worth more than $147,220.00. Insiders at Johnson & Johnson own 0.2% of the company. Learn More about insider trades at Johnson & Johnson.
Information on this page was last updated on 12/12/2024.

Dominic J. Caruso Insider Trading History at Johnson & Johnson

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/20/2017	Sell	82,591	$136.72	$11,291,841.52	226,693
7/26/2016	Sell	41,146	$125.01	$5,143,661.46	157,819
7/18/2013	Sell	30,000	$90.31	$2,709,300.00

Dominic J. Caruso Buying and Selling Activity at Johnson & Johnson

Johnson & Johnson Company Overview

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Today's Range

Now: $144.47

$142.75

$145.47

50 Day Range

MA: $155.16

$143.58

$165.86

2 Week Range

Now: $144.47

$142.75

$168.85

Volume

17,607,496 shs

Average Volume

7,204,668 shs

Market Capitalization

$347.83 billion

P/E Ratio

20.91

Dividend Yield

3.39%

Beta

0.51

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.